par Burris, Howard A;Awada, Ahmad 
;Kuhn, Josée ;Eckardt, J R;Cobb, P W;Rinaldi, D A;Fields, S;Smith, L;Von Hoff, D D
Référence Anti-cancer drugs, 5, 4, page (394-402)
Publication Publié, 1994-08
;Kuhn, Josée ;Eckardt, J R;Cobb, P W;Rinaldi, D A;Fields, S;Smith, L;Von Hoff, D DRéférence Anti-cancer drugs, 5, 4, page (394-402)
Publication Publié, 1994-08
Article révisé par les pairs
| Titre: |
|
| Auteur: | Burris, Howard A; Awada, Ahmad; Kuhn, Josée; Eckardt, J R; Cobb, P W; Rinaldi, D A; Fields, S; Smith, L; Von Hoff, D D |
| Informations sur la publication: | Anti-cancer drugs, 5, 4, page (394-402) |
| Statut de publication: | Publié, 1994-08 |
| Sujet CREF: | Sciences bio-médicales et agricoles |
| MeSH keywords: | Adult |
| Aged | |
| Antineoplastic Agents -- adverse effects | |
| Antineoplastic Agents -- pharmacokinetics | |
| Antineoplastic Agents -- therapeutic use | |
| Camptothecin -- adverse effects | |
| Camptothecin -- analogs & derivatives | |
| Camptothecin -- pharmacokinetics | |
| Camptothecin -- therapeutic use | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Infusions, Intravenous | |
| Male | |
| Middle Aged | |
| Neoplasms -- drug therapy | |
| Neoplasms -- metabolism | |
| Topotecan | |
| Note générale: | Clinical Trial |
| Clinical Trial, Phase I | |
| Journal Article | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0959-4973 |
| info:doi/10.1097/00001813-199408000-00002 | |
| info:pmid/7949242 |
